Mortality Reduction with GLP-1 Receptor Agonist Use in T2D
Patientes with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with obstructive sleep apnea (OSA).
A study presented at CHEST 2025, found a 20 percent greater mortality benefit in the obstructive sleep apnea population.
- T2DM without OSA prescribed metformin without GLP-1 RAs (60.2 percent)
- T2DM without OSA prescribed metformin and GLP-1 RAs (20.1 percent)
- T2DM with OSA prescribed metformin without GLP-1 RAs (11 percent)
Patients with T2DM prescribed GLP-1 RAs have significantly lower one-year mortality.
Author's summary: GLP-1 RAs reduce mortality in T2D patients, especially with OSA.